← Back to Search

Rho kinase inhibitor and Prostaglandin analogue

Rocklatan for Glaucoma

Phase 4
Waitlist Available
Research Sponsored by Aerie Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 0 pretreatment), week 12
Awards & highlights

Study Summary

This trial will compare the efficacy of Rocklatan to latanoprost alone or in combination with another IOP-lowering medication in patients with glaucoma or ocular hypertension.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 0 pretreatment), week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 0 pretreatment), week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12

Side effects data

From 2023 Phase 4 trial • 136 Patients • NCT05283395
22%
Conjunctival hyperaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rocklatan (Latanoprost +1)
Rocklatan (Latanoprost +2)
Rocklatan (Latanoprost Mono)

Trial Design

1Treatment groups
Experimental Treatment
Group I: RocklatanExperimental Treatment1 Intervention
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
2022
Completed Phase 4
~140

Find a Location

Who is running the clinical trial?

Aerie PharmaceuticalsLead Sponsor
38 Previous Clinical Trials
8,190 Total Patients Enrolled
24 Trials studying Glaucoma
6,180 Patients Enrolled for Glaucoma
Scientific Advisor, Clinical R&DStudy DirectorAlcon Research, LLC
Michelle S Senchyna, PhDStudy DirectorAerie Pharmaceuticals
1 Previous Clinical Trials
40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

At what number of facilities is this trial currently operational?

"Patients are currently being recruited at California Eye Specialists Medical Group in Pasadena, Shettle Eye Research in Largo and Vistar Eye Center in Roanoke; 21 additional medical centres are also participating."

Answered by AI

Has this intervention received regulatory authorization from the FDA?

"Our experts at Power graded this therapy with a 3 out of 3, given its Phase 4 status and the attendant approval."

Answered by AI

What is the sample size for this research project?

"Aerie Pharmaceuticals, the trial sponsor, is aiming to recruit 160 eligible participants from two clinical sites: California Eye Specialists Medical Group in Pasadena, California and Shettle Eye Research in Largo, Florida."

Answered by AI

Is this clinical study currently accepting enrollees?

"According to the data published on clinicaltrials.gov, it is evident that this trial is still open for enrolment. The study was initially posted on March 28th 2022 and modified most recently November 10th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Pennsylvania
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
2

Why did patients apply to this trial?

i am currently blind.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
Rocklatan® Evaluation
2022. "Rocklatan® Evaluation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05283395.
~45 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top